Davis RE - Search Results

1

PD 90780, a non peptide inhibitor of nerve growth factor's binding to the P75 NGF receptor.

Spiegel K, Agrafiotis D, Caprathe B, Davis RE, Dickerson MR, Fergus JH, Hepburn TW, Marks JS, Van Dorf M, Wieland DM, et al. Spiegel K, et al. Among authors: davis re. Biochem Biophys Res Commun. 1995 Dec 14;217(2):488-94. doi: 10.1006/bbrc.1995.2802. Biochem Biophys Res Commun. 1995. PMID: 7503726

2

Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor.

Jaen JC, Laborde E, Bucsh RA, Caprathe BW, Sorenson RJ, Fergus J, Spiegel K, Marks J, Dickerson MR, Davis RE. Jaen JC, et al. Among authors: davis re. J Med Chem. 1995 Oct 27;38(22):4439-45. doi: 10.1021/jm00022a008. J Med Chem. 1995. PMID: 7473570

3

Pharmacologic activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys.

Davis RE, Callahan MJ, Dickerson M, Downs DA. Davis RE, et al. J Pharmacol Exp Ther. 1992 Jun;261(3):1044-9. J Pharmacol Exp Ther. 1992. PMID: 1318369

4

Therapeutic intervention in dementia.

Davis RE, Emmerling MR, Jaen JC, Moos WH, Spiegel K. Davis RE, et al. Crit Rev Neurobiol. 1993;7(1):41-83. Crit Rev Neurobiol. 1993. PMID: 8096799 Review.

5

Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist.

Tecle H, Barrett SD, Lauffer DJ, Augelli-Szafran C, Brann MR, Callahan MJ, Caprathe BW, Davis RE, Doyle PD, Eubanks D, Lipiniski W, Mirzadegan T, Moos WH, Moreland DW, Nelson CB, Pavia MR, Raby C, Schwarz RD, Spencer CJ, Thomas AJ, Jaen JC. Tecle H, et al. Among authors: davis re. J Med Chem. 1998 Jul 2;41(14):2524-36. doi: 10.1021/jm960683m. J Med Chem. 1998. PMID: 9651157

6

CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology.

Tecle H, Schwarz RD, Barrett SD, Callahan MJ, Caprathe BW, Davis RE, Doyle P, Emmerling M, Lauffer DJ, Mirzadegan T, Moreland DW, Lipiniski W, Nelson C, Raby C, Spencer C, Spiegel K, Thomas AJ, Jaen JC. Tecle H, et al. Among authors: davis re. Pharm Acta Helv. 2000 Mar;74(2-3):141-8. doi: 10.1016/s0031-6865(99)00027-8. Pharm Acta Helv. 2000. PMID: 10812951

7

Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein.

Emmerling MR, Moore CJ, Doyle PD, Carroll RT, Davis RE. Emmerling MR, et al. Among authors: davis re. Biochem Biophys Res Commun. 1993 Nov 30;197(1):292-7. doi: 10.1006/bbrc.1993.2474. Biochem Biophys Res Commun. 1993. PMID: 8250938

8

PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.

Emmerling MR, Gregor VE, Schwarz RD, Scholten JD, Callahan MJ, Lee C, Moore CJ, Raby C, Lipinski WJ, Davis RE. Emmerling MR, et al. Among authors: davis re. Mol Neurobiol. 1994 Aug-Dec;9(1-3):93-106. doi: 10.1007/BF02816108. Mol Neurobiol. 1994. PMID: 7888109

9

The role of arachidonic acid in the secretion of the amyloid precursor protein (APP).

Emmerling MR, Dudley DT, Dyer RD, Carroll RT, Doyle PD, Davis RE. Emmerling MR, et al. Among authors: davis re. Ann N Y Acad Sci. 1996 Jan 17;777:310-5. doi: 10.1111/j.1749-6632.1996.tb34438.x. Ann N Y Acad Sci. 1996. PMID: 8624105

10

In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.

Jaen J, Barrett S, Brann M, Callahan M, Davis R, Doyle P, Eubanks D, Lauffer D, Lauffer L, Lipinski W, et al. Jaen J, et al. Life Sci. 1995;56(11-12):845-52. doi: 10.1016/0024-3205(95)00019-3. Life Sci. 1995. PMID: 10188784

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

964 results

Search Page

Filters